|
Date:
|
Title:
|
|
03/17/08
|
Migraine Trial - Upcoming 97-center Study of Drug for Acute Pain Stage Announced
This trial – ClinicalTrials.gov ID # NCT00573170 – will be recruiting at 97 centers across the U.S. and will compare 6 possible treatment sequences.
|
|
01/17/08
|
Asthma Drug Trial Recruiting Now at 70 Locations Across US and 11 Other Countries
This large-scale trial will study the effectiveness and safety of a new type of bronchodilating drug providing 24-hour symptom control with one dose. [No longer actively recruiting.]
|
|
10/31/05
|
More than One Million Americans Helped in 6 Months by Private-Sector Drug Program
In just six months, the Partnership for Prescription Assistance (PPA), a national program dedicated to helping people in need access prescription medicines, has matched more than one million patients with assistance programs that likely meet their needs.
|
|
09/07/05
|
AMBIEN CR(TM) (Zolpidem Tartrate Extended-Release Tablets) CIV Receives FDA Approval for the Treatment of Insomnia
Sanofi-aventis (NYSE: SNY; EURONEXT: SAN) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR(TM) (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number one prescription sleep aid, AMBIEN(R) (zolpidem tartrate) CIV, for the treatment of insomnia.
|
|
06/15/05
|
FDA MedWatch - COX-2 Selective and Non-Selective NSAIDs : Safety labeling changes
FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products.
|
|
06/03/05
|
FDA MedWatch - Children's Tylenol nationwide recall due to packag ing that may lead to improper dosing
McNeil Specialty Pharmaceuticals and FDA notified consumers and healthcare professionals about a nationwide recall of all lots and all flavors of Children's TYLENOL Meltaways 80 mg, Children's TYLENOL SoftChews 80mg, and Junior TYLENOL Meltaways 160mg.
|
|
04/27/05
|
New Drug Program Helps More Than 100,000 Patients in First Three Weeks
A new program that helps patients in need get prescription medicines is generating an outpouring of inquiries from patients nationwide.
|
|
04/20/05
|
Study Casts More Doubt on the Safety of Popular Pain Killers
With prescription drugs Vioxx and Bextra already pulled from the market, a study has raised disturbing questions about the heart safety of long-term use of over-the-counter pain relievers such as Advil, Motrin and Aleve.
|
|
04/06/05
|
Sepracor Announces Launch Timing for LUNESTA(TM) Brand Eszopiclone for Treatment of Insomnia
The U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for LUNESTA on December 15, 2004. Data from a landmark, long-term (six-month), double-blind, placebo-controlled safety and efficacy study in 788 patients were reviewed by the FDA as part of the NDA submission for eszopiclone and served as a basis for the FDA's decision to approve LUNESTA for long-term use.
|
|
01/20/05
|
Lunesta: You May Want to Sleep on It
In the next several weeks consumers will see splashy print and television ads touting the lyrically named Lunesta, which was approved last month by the U.S. Food and Drug Administration (FDA). Unlike other sleeping pills, including market leader Ambien, which are not supposed to be taken for longer than 10 days at a time, Lunesta has no FDA recommended time limit.
|
